Pharmacy Times August 5, 2024
The mRNA-1345 vaccine provides a one-off mechanism of protection because of its single-dose prefilled syringes
Researchers from University of Illinois in Chicago assessed key differences among the 3 approved respiratory syncytial virus (RSV) vaccines—RSVPreF3 (Arexvy; GSK), RSVpreF (Abrysvo; Pfizer,) and mRNA-1345 (mRESVIA; Moderna). The study authors noted that health care providers should be aware of current information on each vaccine to aid patient recommendations on RSV immunizations.1
The CDC describes RSV as a common respiratory virus that causes mild, cold-like symptoms, severely impacting infants and older adults. The virus is often spread airborne, through sneezing or coughing, as well as direct contact and contaminated surfaces. RSV hits its peak season in the winter in the US; however cases can begin...
Today's Sponsors
Today's Sponsor